Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-07-14 Proxy Solicitation & In…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
PREN14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically a preliminary proxy statement related to a special meeting of stockholders. It includes detailed information about proposals to increase the size of the board and elect new directors, voting instructions, and background on the solicitation. The document is not an annual report, earnings release, or financial report but rather a solicitation of proxies for voting on corporate governance matters. This fits the definition of a Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed proxy-related information, confirming it is the proxy statement itself, not just an announcement. Therefore, the correct classification is PSI with high confidence.
2022-07-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content specifically mentions a change in the date of a previously announced special meeting of stockholders. There are no financial statements, detailed financial data, or comprehensive reports included. The document is short (2980 characters) and serves as a notification of an event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-07-13 English
DFAN14A
Proxy Solicitation & Information Statement
2022-07-11 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 8, 2022. It reports an event where an activist shareholder requested a special meeting to propose increasing the board size and elect new directors. The document includes details about the shareholder's ownership, the board's response, and the scheduling of the special meeting. There are no financial statements or detailed financial data present. The content focuses on a corporate governance event related to board composition and shareholder proposals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or proposals related to the company's board of directors or senior management.
2022-07-11 English
4
Director's Dealing
2022-07-09 English
3
Director's Dealing
2022-07-09 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.